Floatz logo

68GaNOTA-Anti-HER2 VHH1

Salivary Gland Cancer

Universitair Ziekenhuis BrusselradiopharmaceuticalPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

9 Active assets in the Salivary Gland Cancer cohort.

Asset / SponsorPhaseRating
Carboplatin
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2BB
TRASTUZUMAB
Genentech, Inc.
Phase 2BB
Cetuximab
Fox Chase Cancer Center
Phase 1/2B
Pembrolizumab
OncoC4, Inc.
Phase 2B
Irinotecan
AIDS Malignancy Consortium
Phase 1/2B

View all 42 →

Same molecule, other indications

68GaNOTA-Anti-HER2 VHH1 is also rated in:

breast carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
malignant pancreatic neoplasmDormant
CCC
Indicative ·
53 / 100
View asset →
HER2 positive breast carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →